Previous close | 0.3500 |
Open | 0.3500 |
Bid | 0.3550 x 281200 |
Ask | 0.3600 x 14158300 |
Day's range | 0.3500 - 0.3550 |
52-week range | 0.2500 - 0.7700 |
Volume | |
Avg. volume | 125,370 |
Market cap | 38.501M |
Beta (5Y monthly) | 2.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0910 |
Earnings date | 20 Aug 2022 - 24 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease, has together with its manufacturing partner Andon filed a 510(k) premarket submission with the U.S. Food and Drug Administration (FDA) for the CONNEQT Pulse (Pulse) – a world first dual blood pressure and arterial health monitor targeted at the home health, remote patient monitoring, and decentralized clinical trial markets.
CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease and vascular health disorders, is pleased to announce the appointment of Lesa Musatto to its Board of Directors as a US-based Non-executive Director, effective immediately. The onboarding comes at a time in which CardieX is pursuing a US exchange listing while its subsidiary, CONNEQT, is gearing up to launch multiple new consumer heart-health devices and apps. With her 30 years of global experience i
CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease and vascular health disorders, today announces the addition of notable experts in the health and fitness spaces. Jack Seitz and Lara Rosenbaum have been appointed to the executive team of CardieX's subsidiary, CONNEQT, a new consumer health company that will focus on home vital signs monitors, wearables and consumer health apps.